POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.

More than 6500 patients were included in the study and only 1% show the POLE mutation. Such rare biomarker are important to define in precision cancer medicine, but also raises important questions about how to identify and implement them in practice.


Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
The Lancet Gastroenterology & Hepatology
Available online 20 July 2016
DOI: http://dx.doi.org/10.1016/S2468-1253(16)30014-0

The KG Jebsen Centre for Colorectal Cancer Research home page - colorectal.no

Home page of Raghild A. Lothe's "Gentics" group 

Home page of Arild Nesbakken's "Colorectal surgery" research group

Page visits: 8319